激酶死亡的BRAF和瘤性RAS合作,通过CRAF驱动瘤进展
Sonja J Heidorn1, Carla Milagre, Steven Whittaker
1The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK.
Cell
|February 10, 2010
概括
酶死亡的BRAF和瘤性RAS合作驱动瘤生长. BRAF 抑制剂激活了这种途径,突出显示了在治疗前需要瘤基因定型,以预测患者的反应和不良反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症信号传递 癌症信号传递
背景情况:
- 瘤性RAS突变是癌症的常见驱动因素.
- 在细胞增殖和生存中,BRAF信号通路至关重要.
- 在癌症治疗中使用抑制BRAF的向疗法.
研究的目的:
- 阐明一种新的瘤发生机制,涉及酶死亡的BRAF和瘤性RAS.
- 调查BRAF选择性抑制剂在瘤性RAS背景下的作用.
- 了解对临床实践和患者分层的影响.
主要方法:
- 试管体内激酶测试以评估蛋白质相互作用和信号传递.
- 基于细胞的测试来测量MEK-ERK通路的激活.
- 黑色素瘤的体内小鼠模型用于研究瘤发生.
主要成果:
- 在酶死亡的BRAF,在瘤性RAS的存在下,促进瘤发生.
- 选择性BRAF抑制剂诱导RAS依赖的BRAF与CRAF结合,从而激活MEK-ERK通路.
- 这种途径的激活在瘤性BRAF抑制时不会发生.
- 酶死亡的BRAF和瘤性RAS合作在小鼠中诱导黑色素瘤.
结论:
- 在瘤进展中确定了BRAF介导信号的新范式.
- 了解途径信号和瘤基因定型对于有效的BRAF向治疗至关重要.
- 基因定型可以识别可能对BRAF抑制剂有反应的患者和那些有不良反应风险的患者.
相关概念视频
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:


